Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Activiomics Signs Research Agreement with Kyowa Hakko Kirin

Published: Friday, November 23, 2012
Last Updated: Friday, November 23, 2012
Bookmark and Share
Company signs agreement as part of its strategic partnership with BioFocus.

Activiomics has announced that it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin.

Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems.

This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.

Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyze and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.

“We’ve engaged with Activiomics because we recognize that Activiomics’ label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers” said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.

Dr Neil Torbett, COO of Activiomics, said: “We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics’ first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action”.

Dr Chris Newton, Managing Director of BioFocus, commented “BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus’ drug discovery capabilities and Activiomics’ phosphoproteomics platform for the furtherance of our clients’ projects”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Activiomics Extends Agreement with Kyowa Hakko Kirin
Activiomics announced it has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin (KHK) by entering into a new research programme.
Thursday, September 19, 2013
Activiomics Announces Appointment of Non-Executive Chairman
Dr Trevor Nicholls appointed as Non-executive chairman.
Wednesday, March 28, 2012
Scientific News
Breaking Cell Barriers with Retractable Protein Nanoneedles
Adapting a bacterial structure, institute researchers have developed protein actuators that can mechanically puncture cells.
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
A Crystal Clear View of Biomolecules
Fundamental discovery triggers paradigm shift in crystallography.
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
NIH Seeks Research Applications to Study Zika in Pregnancy, Developing Fetus
Institute has announced that the new effort seeks to understand virus effect on reproduction and child development.
Iron in the Blood Could Cause Cell Damage
Concentrations of iron similar to those delivered through standard treatments can trigger DNA damage within 10 minutes, when given to cells in the laboratory.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!